Exemestane With Sunitinib (SUTENT®) in Metastatic Breast Cancer
Status:
Terminated
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
The investigators want to find out if the treatments used in this study are helpful to
patients that are diagnosed with hormone receptor positive metastatic breast cancer. The
investigators want to also look at any side effects that could happen while patients are on
the study treatments. The investigators want to see if there are any changes that could show
us if your cancer is responding to the study treatments.